Neogenomics, Inc. (NEO): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução da oncologia de precisão, a Neogenomics, Inc. (NEO) surge como uma força transformadora, revolucionando o diagnóstico do câncer por meio de tecnologias genômicas de ponta. Ao integrar perfeitamente testes moleculares avançados, parcerias de pesquisa colaborativa e soluções de diagnóstico personalizadas, a empresa está redefinindo como médicos e pesquisadores abordam a detecção, compreensão e tratamento do câncer. Essa lona abrangente do modelo de negócios revela o plano estratégico que impulsiona a neogenômica de um serviço de laboratório especializado a um participante central no ecossistema genômico de saúde, oferecendo informações sem precedentes que podem potencialmente alterar a trajetória do gerenciamento de câncer.

Neogenomics, Inc. (NEO) - Modelo de Negócios: Parcerias -Chaves

Centros de pesquisa oncológicos e instituições acadêmicas

A Neogenomics estabeleceu parcerias com as seguintes instituições de pesquisa:

Instituição	Foco de colaboração
MD Anderson Cancer Center	Pesquisa de oncologia de precisão
Universidade de Stanford	Desenvolvimento de testes genômicos
Clínica Mayo	Análise de biomarcadores de ensaio clínico

Empresas farmacêuticas e de biotecnologia

As principais parcerias farmacêuticas incluem:

• Merck & Co.
• Bristol Myers Squibb
• AstraZeneca
• Pfizer

Provedores de saúde e hospitais

Rede de Saúde	Detalhes da parceria	Volume anual de teste
Hackensack Meridian Health	Teste abrangente de oncologia	45.000 testes/ano
Memorial Sloan Kettering	Perfil molecular avançado	38.000 testes/ano

Equipamentos de laboratório e fornecedores de tecnologia

Parceiros de tecnologia primária:

• Illumina (plataformas de sequenciamento de próxima geração)
• Thermo Fisher Scientific
• Diagnóstico da Roche

Redes de ensaios clínicos e organizações de pesquisa

Organização	Tipo de parceria	Ensaios ativos
Rede de pesquisa de câncer Swog	Ensaios clínicos de oncologia	27 ensaios ativos
Grupo de Pesquisa sobre Câncer Ecog-Acrina	Estudos de perfil molecular	19 ensaios ativos

Ecossistema total de parceria: 42 colaborações institucionais ativas a partir de 2024

Neogenomics, Inc. (NEO) - Modelo de negócios: Atividades -chave

Teste genético e molecular para diagnóstico de câncer

A neogenômica realizou 585.000 testes moleculares em 2022. A Companhia processou aproximadamente 1,2 milhão de testes em sua rede de laboratórios. A receita de testes genéticos atingiu US $ 499,2 milhões em 2022.

Categoria de teste	Volume (2022)	Impacto de receita
Testes de oncologia de precisão	385,000	US $ 327,4 milhões
Testes de diagnóstico molecular	200,000	US $ 171,8 milhões

Desenvolvendo tecnologias avançadas de teste genômico

A Neogenomics investiu US $ 75,4 milhões em pesquisa e desenvolvimento em 2022. A Companhia mantém 14 laboratórios certificados e credenciados por CLIA, especializados em tecnologias genômicas avançadas.

• Plataformas de sequenciamento de próxima geração (NGS)
• Tecnologias abrangentes de perfil genômico
• Capacidades de teste de biópsia líquida

Fornecendo soluções de medicina de precisão

A empresa processou 165.000 testes de medicina de precisão em 2022, gerando US $ 213,6 milhões em receita especializada em testes de oncologia.

Serviço de Medicina de Precisão	Volume de teste	Receita
Orientação de terapia direcionada	95,000	US $ 122,7 milhões
Detecção de biomarcadores	70,000	US $ 90,9 milhões

Conduzindo ensaios clínicos e pesquisas

A Neogenomics participou de 87 ensaios clínicos em 2022, com colaborações de pesquisa totalizando US $ 42,3 milhões em financiamento externo.

• Pesquisa clínica focada em oncologia
• Parcerias da empresa farmacêutica
• Colaborações da Instituição Acadêmica

Oferecendo serviços de laboratório e consultoria

Os serviços de laboratório geraram US $ 612,5 milhões em receita total para 2022. A Companhia mantém uma rede de 14 instalações de laboratório nos Estados Unidos.

Categoria de serviço	Receita	Base de clientes
Serviços de Laboratório Clínico	US $ 475,3 milhões	2.300+ Provedores de Saúde
Consultoria farmacêutica	US $ 137,2 milhões	180+ empresas farmacêuticas

Neogenomics, Inc. (Neo) - Modelo de Negócios: Recursos -Principais

Tecnologias avançadas de teste genético

A Neogenomics opera com tecnologias avançadas, incluindo:

• Plataformas de sequenciamento de próxima geração (NGS)
• Sistemas de diagnóstico molecular
• Equipamento de teste citogenético

Categoria de tecnologia	Investimento de equipamentos	Custo de manutenção anual
Plataformas NGS	US $ 12,3 milhões	US $ 1,7 milhão
Sistemas de diagnóstico molecular	US $ 8,6 milhões	US $ 1,2 milhão
Equipamento de teste citogenético	US $ 5,4 milhões	$850,000

Infraestrutura de laboratório especializada

A neogenômica mantém 7 laboratórios certificados pela CLIA Nos Estados Unidos, com espaço total de laboratório de aproximadamente 120.000 pés quadrados.

Profissionais científicos e médicos altamente qualificados

Composição da força de trabalho a partir de 2024:

• Total de funcionários: 1.236
• Cientistas do nível de doutorado: 187
• Patologistas certificados pela placa: 64
• Cientistas do Laboratório Clínico: 412

Bancos de dados genômicos proprietários e plataformas de pesquisa

Tipo de banco de dados	Total de registros	Taxa de atualização anual
Banco de dados genômico do câncer	528.000 registros de pacientes	17.3%
Repositório de Biomarcadores Oncológicos	276.000 perfis moleculares	14.6%

Propriedade intelectual e patentes de pesquisa

Portfólio de patentes a partir de 2024:

• Total de patentes ativas: 37
• Patentes do método de teste genômico: 22
• Patentes de Tecnologia de Diagnóstico: 15

Neogenomics, Inc. (Neo) - Modelo de Negócios: Proposições de Valor

Teste abrangente de oncologia de precisão

A Neogenomics oferece mais de 3.400 testes moleculares e de patologia, com foco no diagnóstico do câncer. A empresa processou 667.000 casos em 2022, gerando US $ 687,4 milhões em receita total.

Categoria de teste	Número de testes	Utilidade clínica
Perfil molecular	1.850 testes exclusivos	Insights genômicos específicos para o câncer
Serviços de patologia	1.550 testes especializados	Caracterização detalhada do câncer

Soluções de diagnóstico de câncer personalizadas

A neogenômica fornece Testes genéticos personalizados com taxa de precisão de 98,7% em vários tipos de câncer.

• Perfil genômico abrangente
• Análise de mutação direcionada
• Identificação do biomarcador

Detecção precoce e recomendações de tratamento direcionadas

As plataformas de teste da empresa suportam a detecção precoce de câncer com 92,4% de sensibilidade nos principais tipos de câncer.

Tipo de câncer	Sensibilidade à detecção	Terapias direcionadas
Câncer de pulmão	94.2%	25 terapias direcionadas
Câncer de mama	93.7%	18 terapias direcionadas

Idéias genômicas avançadas para médicos

A Neogenomics atende a mais de 3.800 parceiros clínicos com serviços abrangentes de relatórios e consultas.

• Interpretação genômica em tempo real
• Combinação de ensaios clínicos
• Consulta de estratégia de tratamento

Serviços inovadores de perfil molecular

A empresa investiu US $ 82,3 milhões em P&D durante 2022, com foco em tecnologias avançadas de perfil molecular.

Tecnologia	Investimento em P&D	Recursos exclusivos
Sequenciamento de próxima geração	US $ 42,1 milhões	Paisagem genômica abrangente
Tecnologias de biópsia líquida	US $ 40,2 milhões	Detecção de câncer não invasiva

Neogenomics, Inc. (Neo) - Modelo de Negócios: Relacionamentos do Cliente

Vendas diretas e gerenciamento de contas

A Neogenomics mantém uma equipe de vendas dedicada de 87 representantes de vendas diretas a partir de 2023. A abordagem de vendas direta da empresa tem como alvo laboratórios de oncologia, hospitais e empresas farmacêuticas.

Segmento de clientes	Número de contas	Contribuição anual da receita
Laboratórios de Oncologia	425	US $ 187,3 milhões
Hospitais	312	US $ 142,6 milhões
Empresas farmacêuticas	156	US $ 98,7 milhões

Plataformas de suporte ao cliente online

A Neogenomics oferece suporte on -line abrangente por meio de:

• Portal de clientes digitais 24/7
• Sistema de rastreamento de resultados de teste em tempo real
• Plataforma de gerenciamento de documentos seguros

Canal de suporte	Tempo médio de resposta	Taxa de satisfação do cliente
Portal online	2,3 horas	92%
Suporte por e -mail	4,1 horas	87%
Suporte telefônico	15 minutos	95%

Parcerias de pesquisa colaborativa

A neogenômica se envolve em colaborações de pesquisa estratégica com 43 instituições acadêmicas e 28 organizações de pesquisa farmacêutica em 2023.

Tipo de parceria	Número de parcerias ativas	Investimento anual de pesquisa
Instituições acadêmicas	43	US $ 12,5 milhões
Organizações de pesquisa farmacêutica	28	US $ 18,3 milhões

Atualizações contínuas de tecnologia e serviço

A Neogenomics investe US $ 37,6 milhões anualmente em pesquisa e desenvolvimento, com 62 projetos de aprimoramento de tecnologia em andamento em 2023.

Webinars educacionais e conferências científicas

A empresa hospeda e participa de vários eventos científicos anualmente:

• 12 webinars internos
• 24 apresentações de conferência externa
• 8 simpósios científicos patrocinados

Tipo de evento	Número de eventos	Alcance estimado dos participantes
Webinars internos	12	3.500 participantes
Apresentações externas da conferência	24	7.200 participantes
Simpósios científicos patrocinados	8	2.100 participantes

Neogenomics, Inc. (Neo) - Modelo de Negócios: Canais

Equipe de vendas diretas

A equipe de vendas direta da Neogenomics consiste em 154 representantes de vendas a partir do quarto trimestre de 2023. A equipe gera aproximadamente US $ 481,2 milhões em receita anual por meio de interações diretas de clientes.

Segmento da equipe de vendas	Número de representantes	Mercado -alvo
Especialistas em oncologia	87	Clínicas de oncologia
Especialistas em biopharma	42	Empresas farmacêuticas
Especialistas em pesquisa acadêmica	25	Instituições de pesquisa

Plataformas digitais online

A Neogenomics opera vários canais digitais gerando 22,3% da receita total em 2023, com uma receita estimada em plataforma on -line de US $ 103,5 milhões.

• Sistema de pedidos baseado na Web
• Plataforma de relatório de resultados digitais
• Sistema de Gerenciamento de Informações de Laboratório Integrado

Conferências médicas e feiras

Em 2023, a Neogenomics participou de 37 conferências médicas internacionais, com um investimento estimado em redes e geração de leads de US $ 2,4 milhões.

Tipo de conferência	Número de conferências	Alcance estimado
Conferências de oncologia	22	15.000 profissionais
Eventos de Medicina de Precisão	9	7.500 profissionais
Simpósios de Biopharma	6	5.000 profissionais

Redes de referência profissional de saúde

A Neogenomics mantém relacionamentos com 6.782 profissionais de saúde em 1.243 instituições médicas, gerando receita baseada em referência de aproximadamente US $ 76,9 milhões em 2023.

Serviços de telemedicina e consulta digital

Os serviços de consulta digital representam 8,6% da receita total, com US $ 40,2 milhões gerados por meio de plataformas de consulta de aconselhamento genético remoto e testes moleculares em 2023.

• Sessões de aconselhamento genético virtual
• Interpretação de testes moleculares remotos
• Consultas de patologia digital

Neogenomics, Inc. (NEO) - Modelo de negócios: segmentos de clientes

Oncologistas e centros de tratamento de câncer

A Neogenomics atende a aproximadamente 3.000 práticas de oncologia e centros de tratamento de câncer nos Estados Unidos.

Tipo de cliente	Número de clientes	Volume de teste anual
Práticas de oncologia	2,500	Mais de 450.000 testes anualmente
Centros de Tratamento do Câncer	500	Aproximadamente 250.000 testes anualmente

Organizações de pesquisa farmacêutica

A Neogenomics suporta mais de 100 organizações de pesquisa farmacêutica com serviços de testes genômicos especializados.

• 20 principais empresas farmacêuticas como clientes
• Suporta aproximadamente 75 ensaios clínicos anualmente
• Volume de teste genômico para pesquisa: 150.000 amostras por ano

Patrocinadores de ensaios clínicos

A empresa colabora com aproximadamente 250 patrocinadores de ensaios clínicos em várias áreas terapêuticas.

Tipo de teste	Número de patrocinadores	Contratos médios anuais
Ensaios Oncológicos	175	US $ 45 milhões em pesquisa contratada
Outras áreas terapêuticas	75	US $ 15 milhões em pesquisa contratada

Pacientes individuais que buscam testes genéticos

A neogenômica processa aproximadamente 250.000 testes genéticos de pacientes individuais anualmente.

• Testes genéticos de câncer: 180.000 pacientes
• Triagem hereditária de câncer: 70.000 pacientes
• Preço médio de teste: US $ 1.200 - US $ 3.500

Provedores de seguros de saúde

A Neogenomics tem contratos com 85% dos principais provedores de seguros de saúde nos Estados Unidos.

Categoria de provedor de seguros	Número de contratos	Volume anual de reembolso
Seguradoras nacionais	12	US $ 280 milhões
Seguradoras regionais	45	US $ 120 milhões

Neogenomics, Inc. (Neo) - Modelo de Negócios: Estrutura de Custo

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Neogenomics registrou despesas de P&D de US $ 96,3 milhões, representando 21,4% da receita total.

Equipamentos de laboratório e investimentos em tecnologia

Categoria de equipamento	Valor do investimento (2023)
Plataformas de sequenciamento de próxima geração	US $ 12,5 milhões
Instrumentos de diagnóstico molecular	US $ 8,7 milhões
Sistemas de análise computacional	US $ 6,3 milhões

Pessoal e salários especializados da equipe científica

As despesas totais de pessoal para 2023 foram de US $ 218,6 milhões, com um salário médio para a equipe científica que varia de US $ 85.000 a US $ 145.000 anualmente.

• Patologistas moleculares: salário médio de US $ 127.500
• Cientistas de pesquisa: salário médio de US $ 98.000
• Tecnólogos genéticos: salário médio de US $ 72.000

Ensaios clínicos e financiamento de pesquisa

O financiamento da pesquisa clínica para 2023 totalizou US $ 42,1 milhões, alocados em múltiplas iniciativas de pesquisa de oncologia e medicina de precisão.

Infraestrutura de marketing e vendas

Categoria de despesa de marketing	Despesas (2023)
Marketing digital	US $ 3,7 milhões
Compensação da equipe de vendas	US $ 22,4 milhões
Participação de conferência e evento	US $ 1,9 milhão

Custos operacionais totais para 2023: US $ 393,4 milhões

Neogenomics, Inc. (NEO) - Modelo de negócios: fluxos de receita

Taxas de serviço de teste de diagnóstico

A Neogenomics relatou receita total de US $ 532,8 milhões para o ano fiscal de 2022. Os serviços de teste de diagnóstico foram responsáveis ​​pela maior parte desta receita.

Categoria de serviço	Receita (2022)	Porcentagem da receita total
Teste de diagnóstico de oncologia	US $ 412,3 milhões	77.4%
Segmento de serviços farmacêuticos	US $ 120,5 milhões	22.6%

Contratos de apoio ao ensaio clínico

A neogenômica gerou US $ 129,1 milhões em serviços farmacêuticos e apoio aos ensaios clínicos em 2022.

• Valor médio do contrato para testes genômicos de ensaios clínicos: US $ 250.000 a US $ 1,5 milhão
• Número de contratos ativos de ensaios clínicos farmacêuticos: 87

Colaborações de pesquisa farmacêutica

As colaborações de pesquisa farmacêutica contribuíram com US $ 85,6 milhões para a receita da empresa em 2022.

Tipo de colaboração	Contribuição da receita	Número de parcerias ativas
Colaborações de pesquisa oncológica	US $ 62,3 milhões	23
Colaborações de medicina de precisão	US $ 23,3 milhões	12

Serviços de consulta de medicina de precisão

Os serviços de consulta de medicina de precisão geraram US $ 37,4 milhões em receita para 2022.

• Taxa média de serviço de consulta: US $ 5.000 a US $ 50.000
• Número total de clientes de consulta: 742

Vendas de kits de teste genético

As vendas do kit de testes genéticos atingiram US $ 18,2 milhões em 2022.

Tipo de kit	Volume de vendas	Preço médio do kit
Kits de testes genéticos oncológicos	24.600 unidades	$650
Kits de triagem genética abrangente	11.300 unidades	$350

NeoGenomics, Inc. (NEO) - Canvas Business Model: Value Propositions

You're looking at what NeoGenomics, Inc. offers to its customers-the core reasons why oncologists, hospital systems, and biopharma partners choose them over the competition. It's all about breadth, speed, and actionable data in the complex world of cancer diagnostics.

The first big value is offering comprehensive oncology testing across the entire cancer continuum. NeoGenomics provides one of the most complete oncology-focused testing menus available, covering the full spectrum of cancer care needs. This breadth is anchored by a menu featuring over 500 oncology-focused tests.

Next, you see the push for innovative diagnostic and predictive testing for precision medicine. This isn't just running tests; it's about delivering deep insights for targeted therapy. For instance, their Comprehensive Genomic Profiling (CGP) panels identified actionable alterations in 67% of tumors tested, which is more than double the 33% found using a standard 50-gene targeted NGS panel. The PanTracer LBx liquid biopsy test, for example, analyzes a total of 514 genes.

Speed is a major differentiator in oncology, and NeoGenomics delivers with rapid turnaround times. Specifically, the NEO PanTracer LBx liquid biopsy test is designed to offer a seven-day turnaround time (TAT). For their tissue-based tests, the TAT is 8-10 days for PanTracer Tissue and PanTracer Tissue + HRD.

The company helps simplify operational workflows for institutions by consolidating send-out testing. By offering a holistic genomic picture through their PanTracer portfolio, they provide a frictionless, single-source workflow. This consolidation reduces the complexity for institutions managing multiple vendors for different types of testing.

The focus on advanced testing is clearly paying off in the financials, particularly in high-growth NGS testing. In the third quarter of 2025, Next-Generation Sequencing (NGS) revenue grew 24% year-over-year. This high-value segment now accounts for nearly one-third (or 33%) of their total clinical revenue. This growth in high-value testing helped drive the Average Revenue per Clinical Test (AUP) up to $476 in Q3 2025.

Here's a quick look at how their key portfolio elements stack up:

Value Component	Metric/Feature	Associated Number
Comprehensive Coverage	Total Genes Analyzed (PanTracer Portfolio)	Over 500
Precision Medicine Impact	Actionable Alterations Found (CGP vs. 50-gene panel)	67% vs. 33%
Speed of Results	PanTracer LBx Turnaround Time (TAT)	7 days
Growth Engine	NGS Revenue Growth (Q3 2025 YoY)	24%
Clinical Volume	Total Clinical Test Volume (Q3 2025)	361,000 tests

The value proposition is further supported by operational performance metrics from Q3 2025:

• Total Consolidated Revenue reached $188 million.
• Clinical Revenue grew 18% year-over-year.
• Clinical Test Volumes increased 15% year-over-year.
• The company is projecting full-year 2025 revenue between $720 million and $726 million.

They are delivering these results while focusing on integrating acquisitions, like Pathline, which was completed during the third quarter, including the validation of critical TAT-sensitive assays.

NeoGenomics, Inc. (NEO) - Canvas Business Model: Customer Relationships

You're looking at how NeoGenomics, Inc. connects with the oncologists, pathologists, and hospital systems that rely on their specialized cancer testing. It's about making complex diagnostics accessible and actionable for the people treating patients every day. The company's strategy, as CEO Tony Zook noted entering 2025, centers on winning on customer experience while capitalizing on its commercial organization.

The structure for direct engagement relies heavily on a dedicated commercial sales team. NeoGenomics, Inc. has been actively optimizing and expanding this commercial organization throughout 2025. This team includes Oncology Sales Specialists focused on the community oncology segment, a group they expanded in 2024 to increase coverage as new products launched in 2025. While the exact current size of the dedicated sales force isn't public, the company had 2,200 total employees as of September 30, 2025, indicating the scale of the support structure behind these relationships. The acceleration point for contributions from this sales force was anticipated in the second half of 2025.

Consultative services from expert pathologists are a key differentiator, supporting the rapport NeoGenomics, Inc. has established with community pathologists and oncologists. This expert interaction helps translate complex genomic data into clinically actionable reports. The focus on high-value tests, like Next-Generation Sequencing (NGS), which grew 24% year-over-year in Q3 2025, suggests these consultative touchpoints are crucial for adoption.

The patient-centric strategy is designed to directly improve patient care, which is the ultimate measure of customer success. The company delivered a record number of results to patients in the first quarter of 2025. Furthermore, the long-range goal is to serve more than 1 million patients annually by 2028, showing a commitment to scaling this patient impact. This focus is reflected in the clinical volume growth, which increased 15% year-over-year in the third quarter of 2025.

To make doing business easier-a direct driver for customer retention-NeoGenomics, Inc. has heavily invested in its digital ecosystem. This includes direct user interfaces for ordering and accessing results. As of the end of 2024, the company had already implemented over 300 direct user interfaces with customers. This digital push is part of a broader strategy to transform the digital ecosystem, including migrating to a single Laboratory Information Management System (LIMS).

Here's a quick look at some of the key operational metrics that reflect the volume and value flowing through these customer relationships in 2025:

Metric	Period/Date	Value
Total Employees	September 30, 2025	2,200
Direct User Interfaces Implemented (Cumulative)	End of 2024 (Latest Figure)	Over 300
Average Revenue Per Clinical Test	Q3 2025	$476
Clinical Test Volume Growth (YoY)	Q3 2025	15%
NGS Revenue Growth (YoY)	Q3 2025	24%

The company's commitment to customer experience is supported by tangible results in test value and volume, even as they manage headwinds in non-clinical revenue.

• Focus on community oncology segment expansion.
• Goal to achieve 12-13% annual revenue growth for fiscal year 2025.
• NGS now accounts for nearly one-third of clinical revenue as of Q3 2025.
• Adjusted Gross Profit Margin was 47% in Q1 2025.

Finance: draft 13-week cash view by Friday.

NeoGenomics, Inc. (NEO) - Canvas Business Model: Channels

Direct sales force to oncologists, pathologists, and hospitals

NeoGenomics, Inc. capitalizes on a commercial organization focused on the community setting, where approximately 80% of cancer care is delivered. The clinical services sales team is structured across nine regions in the United States. The company noted in its Q2 2025 update that it was 'continuing to grow our sales team.' For pharmaceutical development services, a dedicated team of business development specialists supports sponsors with testing needs for research and development projects, including Phase I, II, and III studies. Sales representatives manage their territories using a custom Customer Relationship Management System (CRM), which integrates key customer care functionality from the Laboratory Information Management System (LIMS) in real time.

Network of full-service, accredited laboratories for sample processing

NeoGenomics, Inc. maintains a network of laboratories across the US that are CAP-accredited and CLIA-certified for full-service sample processing and analysis. This network expanded with the completion of the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory in New Jersey, on April 4, 2025. Internationally, the company operates a CAP-accredited full-service, sample-processing laboratory located in Cambridge, United Kingdom. As of September 30, 2025, NeoGenomics (Fort Myers) had a total employee count of 2,200. The company has a long-range goal to serve more than 1 million patients annually by 2028.

Electronic Health Record (EHR) integration, including EPIC, for streamlined ordering

The company is focused on transforming its digital ecosystem, which includes efforts to enhance integration capabilities. While specific adoption numbers for NeoGenomics, Inc. integrations aren't detailed, industry context shows that it may take 4 to 6 months for an IT team to implement a point-to-point integration with a single reference lab. A 2022 report noted a Maryland cancer institute planned to integrate MEDITECH's Expanse Genomics with several labs, including NeoGenomics. Industry-wide, approximately 85% of EHRs offer seamless integration with laboratory systems for real-time result access.

Digital platforms for test ordering and results reporting

The digital infrastructure supports ordering and reporting, with sales teams relying on the integrated LIMS and CRM. The clinical business performance in Q3 2025 showed strong utilization of advanced digital testing platforms, as Next-Generation Sequencing (NGS) testing grew 24% year-over-year and accounted for nearly one-third of clinical revenue. The average revenue per clinical test in the third quarter of 2025 reached $476. The clinical revenue growth for Q3 2025 was 18% compared to Q3 2024.

Here's a quick look at the key performance metrics relevant to channel output for the third quarter of 2025:

Metric	Value (Q3 2025)	Comparison/Context
Consolidated Revenue	$188 million	Up 12% year-over-year
Clinical Revenue Growth (YOY)	18%	Driven by test volumes
Average Revenue per Clinical Test	$476	Up 3% year-over-year
NGS Revenue Share of Clinical Revenue	Nearly one-third	NGS grew 24% year-over-year
Total Employees	2,200	As of September 30, 2025

Finance: review Q4 2025 sales pipeline conversion rates by region by next Tuesday.

NeoGenomics, Inc. (NEO) - Canvas Business Model: Customer Segments

You're looking at how NeoGenomics, Inc. structures its client base, which is really about where the testing dollars are coming from. As of late 2025, the focus is clearly on the clinical side, especially the community setting, even with headwinds in the pharma sector.

The clinical business is the engine. For the third quarter of 2025, total revenue hit a record of \$188 million, with the clinical business driving an 18% year-over-year growth. This segment is where you find the community practices, hospitals, and academic centers.

The company specifically notes its focus on the community setting, stating that approximately 80% of cancer care is delivered there. This tells you where the sales force and service improvements are directed.

The pharmaceutical and biotech firms fall under the non-clinical revenue bucket, and that area has seen pressure. For instance, in the first quarter of 2025, non-clinical revenue declined by 15.8% year-over-year, which the company anticipated.

Here is a breakdown mapping the required segments to the available financial context from the recent quarters:

Customer Segment Group	Primary Revenue Type Context	Key Metric/Data Point (Latest Available)
Community-based pathology and oncology practices	Clinical Revenue	~80% of cancer care delivered in this setting.
Hospital systems and academic medical centers	Clinical Revenue	Part of the clinical business driving 18% YoY growth in Q3 2025.
Pharmaceutical and biotech firms for clinical trials and research	Non-Clinical Revenue	Declined by 15.8% year-over-year in Q1 2025.
Reference laboratories (send-out testing)	Clinical Revenue	Contributes to overall clinical volume, with Average Revenue Per Test at \$476 in Q3 2025.

Within the clinical revenue stream, Next-Generation Sequencing (NGS) is a key value driver for these customers. In the third quarter of 2025, NGS revenue grew by 24% year-over-year and now accounts for nearly one-third of the total clinical revenue.

You can see the overall revenue mix shift by looking at the Q2 2025 figures, where Clinical Revenue was approximately \$160 million out of total revenue of \$181 million, showing the heavy weighting toward direct patient/provider testing.

The average revenue per clinical test (ARPCT) is a good proxy for the value captured from these segments. For the third quarter of 2025, the ARPCT was \$476, up 3% year-over-year.

The company is actively managing its customer base by focusing on high-value tests and maintaining strong relationships in the community. They are positioning themselves as the partner of choice for clinicians.

• NGS testing now represents nearly one-third of clinical revenue.
• The revised full-year 2025 revenue guidance is between \$720 million and \$726 million.
• Q3 2025 total revenue was \$188 million.
• The company is growing its sales team to strengthen the community channel.

If onboarding for new hospital systems takes longer than expected, it definitely impacts the near-term realization of that segment's potential.

Finance: draft 13-week cash view by Friday.

NeoGenomics, Inc. (NEO) - Canvas Business Model: Cost Structure

You're looking at the hard numbers that drive NeoGenomics, Inc.'s operations as of late 2025. It's a cost-intensive business, built on specialized science and infrastructure.

High compensation and benefit costs for specialized staff represent a major component of the overall spend. For instance, in the third quarter of 2025, the increase in operating expenses included approximately $4.7 million attributed to higher compensation and benefit costs, largely driven by the expansion of the commercial sales team. This reflects the need to staff highly skilled personnel across lab operations and sales.

The commitment to staying ahead in oncology diagnostics means significant R&D investment in new product defintely development is a constant drain on cash flow. Looking at the first nine months of 2025, Research and Development expenses totaled $27,898 thousand, up from $23,190 thousand for the same period in 2024. This investment fuels the development of next-generation MRD products and therapy selection tests.

Total Operating expenses are substantial, reflecting the scale of the laboratory network. For the third quarter of 2025, total operating expenses were reported at $107 million, which was an increase of $11 million, or 12%, compared to the third quarter of 2024. This figure includes non-recurring charges, such as $7.1 million in impairment charges related to the planned sale of Trapelo during Q3 2025.

The core of the cost structure lies in the Costs of supplies and reagents for complex testing. This is captured within the Cost of Revenue. For the three months ended September 30, 2025, the Cost of Revenue was $107,351 thousand. This increase, partially offsetting revenue gains, led to a consolidated gross profit margin of 43% for the quarter, though the Adjusted Gross Profit Margin was 45%.

You also have to account for Acquisition and integration costs as NeoGenomics, Inc. continues to expand its footprint. The acquisition of Pathline, LLC, completed in April 2025, involved an initial cash consideration of $8.0 million, subject to adjustments, plus a contingent consideration of $1.0 million. The company anticipates operational consolidation and synergies from this deal will yield substantial annual cost reductions, expected to be accretive to Adjusted EBITDA starting in 2026.

Here's a quick look at the major expense categories for the three months ended September 30, 2025, compared to the prior year period, in thousands of USD:

Expense Category	3 Months Ended Sep. 30, 2025 (in thousands)	3 Months Ended Sep. 30, 2024 (in thousands)
Cost of Revenue	$107,351	$92,944
General and administrative	$69,874	$66,969
Sales and marketing	$21,806	$20,415
Impairment charges (Note 5)	$7,086	$0
Total Operating Expenses	$107,460	$96,077

The breakdown of operating expenses for the third quarter of 2025 shows where the cash is going:

• General and administrative expenses: $69,874 thousand.
• Sales and marketing expenses: $21,806 thousand.
• Research and development expenses: $8,694 thousand.
• Impairment charges: $7,086 thousand.

The company ended the quarter with $164 million in cash and cash equivalents and marketable securities.

Finance: draft 13-week cash view by Friday.

NeoGenomics, Inc. (NEO) - Canvas Business Model: Revenue Streams

You're looking at how NeoGenomics, Inc. brings in its money as of late 2025. It's primarily a testing and services company focused on oncology.

The company's revenue streams are built around its laboratory services, which are segmented by the type of client and test complexity. You'll see the core business is heavily reliant on clinical volume and pricing power.

For the full year 2025, NeoGenomics, Inc. has provided guidance expecting total revenue in the range of $720 million to $726 million. Furthermore, the company guided for Full-year 2025 Adjusted EBITDA guidance of $41 million to $44 million.

Clinical Services Revenue from Diagnostic Testing (Primary Driver)

This is the bread and butter for NeoGenomics, Inc. It covers the testing ordered by oncologists and pathologists to help diagnose and manage cancer treatment for patients. Strength here drives the overall top line, as seen in recent quarters.

For instance, in the third quarter of 2025, total clinical revenue grew by 18% year-over-year. This growth was fueled by a 15% increase in clinical test volumes and a 3% increase in the average revenue per clinical test, which reached $476. That average price increase reflects a mix shift toward more complex, higher-value tests.

The key components driving this segment include:

• Clinical cancer testing services.
• Interpretation and consultative services.
• Validation laboratory services.

Next-Generation Sequencing (NGS) Testing Revenue (High-Growth Segment)

Next-Generation Sequencing (NGS) is a critical, high-growth component within the broader clinical testing category. These are more advanced, comprehensive genomic tests that provide deeper insights for targeted therapy selection.

NGS has been a standout performer. In the third quarter of 2025, NGS revenue specifically grew by 24% year-over-year. This segment benefits from the overall increase in the average revenue per test because NGS tests carry a higher price point than standard tests.

The table below summarizes some recent quarterly performance metrics that feed into this revenue stream:

Metric	Q3 2025 Value	YoY Growth (Q3 2025 vs Q3 2024)
Total Consolidated Revenue	$188 million	12%
Clinical Revenue Growth	Not explicitly stated	15% increase in clinical test volumes
NGS Revenue Growth	Not explicitly stated	24%
Average Revenue Per Clinical Test	$476	3%

Non-Clinical Revenue from Pharmaceutical and Biotech Research Services

This stream comes from providing testing and lab services to pharmaceutical and biotech companies, often supporting their clinical trials or research and development efforts. This revenue can be more lumpy and less predictable than the core clinical business.

You need to watch this segment closely, as it has shown recent weakness. In the third quarter of 2025, non-clinical revenue declined by 27% versus the prior year, which partially offset the strong performance in the clinical segment. This pressure in pharma revenue was cited as a reason for earlier guidance revisions.

The services falling under this category are:

• Clinical trials and research support.
• Comprehensive technical and professional services offering.
• Oncology data solutions.

It's a smaller piece of the pie right now, but it's important for strategic partnerships.